{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:10:10Z","timestamp":1760044210207,"version":"3.44.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.leukres.2021.106583","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T18:13:44Z","timestamp":1619115224000},"page":"106583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Treatment of myeloid sarcoma without bone marrow involvement with gemtuzumab ozogamicin-containing regimen"],"prefix":"10.1016","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0355-2380","authenticated-orcid":false,"given":"Moayed","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1882-0504","authenticated-orcid":false,"given":"Andrew","family":"Vegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ketaki","family":"Panse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2136-3620","authenticated-orcid":false,"given":"Kshama","family":"Bhyravabhotla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4261-1099","authenticated-orcid":false,"given":"Kendra","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Craig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Safah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nakhle S.","family":"Saba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Socola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.leukres.2021.106583_bib0005","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2021.106583_bib0010","first-page":"265","article-title":"Granulocytic sarcoma: a systematic review","volume":"3","author":"Yilmaz","year":"2013","journal-title":"Am. J. Blood Res."},{"issue":"3","key":"10.1016\/j.leukres.2021.106583_bib0015","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1309\/AJCP1ZA7HYZKAZHS","article-title":"Myeloid sarcoma: extramedullary manifestation of myeloid disorders","volume":"132","author":"Campidelli","year":"2009","journal-title":"Am. J. Clin. Pathol."},{"issue":"22","key":"10.1016\/j.leukres.2021.106583_bib0020","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood-2017-09-797712","article-title":"Gemtuzumab ozogamicin for acute myeloid leukemia","volume":"130","author":"Appelbaum","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2021.106583_bib0025","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/leu.2015.244","article-title":"A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"30","author":"Daver","year":"2016","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.leukres.2021.106583_bib0030","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1080\/1042819042000219485","article-title":"Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas","volume":"45","author":"Piccaluga","year":"2004","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.leukres.2021.106583_bib0035","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1620\/tjem.220.121","article-title":"Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse after allogeneic hematopoietic stem-cell transplantation","volume":"220","author":"Ando","year":"2010","journal-title":"Tohoku J. Exp. Med."},{"issue":"7","key":"10.1016\/j.leukres.2021.106583_bib0040","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1200\/JOP.18.00753","article-title":"Venetoclax for refractory myeloid sarcoma","volume":"15","author":"Kanate","year":"2019","journal-title":"J. Oncol. Pract."},{"issue":"4","key":"10.1016\/j.leukres.2021.106583_bib0045","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00002371-199211000-00008","article-title":"Sequential chemotherapy and immunotherapy for the treatment of metastatic melanoma","volume":"12","author":"Schuchter","year":"1992","journal-title":"J Immunother"},{"issue":"5","key":"10.1016\/j.leukres.2021.106583_bib0050","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.clml.2017.02.027","article-title":"Myeloid sarcoma: presentation, diagnosis, and treatment","volume":"17","author":"Almond","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"6","key":"10.1016\/j.leukres.2021.106583_bib0055","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/cncr.23691","article-title":"Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia","volume":"113","author":"Tsimberidou","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2021.106583_bib0060","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/hon.994","article-title":"Clinical implications of acute myeloid leukemia presenting as myeloid sarcoma","volume":"30","author":"Avni","year":"2012","journal-title":"Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2021.106583_bib0065","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000497210","article-title":"Myeloid sarcoma","volume":"42","author":"Magdy","year":"2019","journal-title":"Oncol. Res. Treat."},{"issue":"2","key":"10.1016\/j.leukres.2021.106583_bib0070","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ijrobp.2018.05.045","article-title":"Use of radiation in extramedullary leukemia\/chloroma: guidelines from the international lymphoma radiation oncology group","volume":"102","author":"Bakst","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"6","key":"10.1016\/j.leukres.2021.106583_bib0075","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/cncr.10399","article-title":"Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature","volume":"94","author":"Yamauchi","year":"2002","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.leukres.2021.106583_bib0080","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.79","article-title":"Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set","volume":"7","author":"Goyal","year":"2017","journal-title":"Blood Cancer J."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621000849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621000849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:01:07Z","timestamp":1758934867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212621000849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":16,"alternative-id":["S0145212621000849"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106583","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of myeloid sarcoma without bone marrow involvement with gemtuzumab ozogamicin-containing regimen","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106583","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106583"}}